Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

The role of RhoA in diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5308.

https://doi.org/10.1182/blood-2025-5308

Published: 2025

Journal Articles

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Blood (2025) 146 (Supplement 1): 90.

https://doi.org/10.1182/blood-2025-90

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Blood (2025) 146 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2025-1937

Published: 2025

Journal Articles

Relapsed diffuse large B-cell lymphoma is shaped by molecular subtypes and genomic alterations

Blood (2025) 146 (Supplement 1): 349.

https://doi.org/10.1182/blood-2025-349

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm-Kuczera, Shashwat Sahay, Meng Wang, Salaheddine Ali, Nazli Serin, Khouloud Kouidri, Donika Tahiri, Sebastian Scheich, Uta Brunnberg, David Winkler, Samixa Pudasaini, Zoi Saxonis, Atef Abdelhafez, Tatiana Borodina, Ulrike Krueger, David Böckle, Corinna Leng, Joseph Kauer, Isabelle Krämer, Konstantinos Christofyllakis, Marcel Teichert, Niklas Gebauer, Ulf Schnetzke, Thomas Weber, Lukas Frenzel, Anna-Carina Hund, Evgenii Shumilov, Thomas Melchardt, Florian Eisele, Mirjeta Berisha, Jakob Rudzki, Christian Scholz, Martin Schmidt-Hieber, Dimitrios Mougiakakos, Johannes Duell, Gerald Wulf, Christian Schmidt, Georg Lenz, Bastian von Tresckow, Hans Christian Reinhardt, Richard Greil, Lorenz Thurner, Peter Dreger, Martin Dreyling, Christiane Pott, Martina Rudelius, Oliver Weigert, Phillipp Strubel, Roland Eils, Antonia Busse, Ulrich Keller, Naveed Ishaque, Björn Chapuy

Blood (2025) 146 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2025-3688

Published: 2025

Journal Articles

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Blood (2025) 146 (Supplement 1): 5494.

https://doi.org/10.1182/blood-2025-5494

Published: 2025

Journal Articles

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay, Chidimma Agatha Akpa, Christina Schniederjohann, Julia Richter, Peter-Martin Bruch, Ulrich Dührsen, Michael Hummel, Andreas Rosenwald, Wolfram Klapper, Sascha Dietrich, Ulrich Keller, Björn Chapuy

Blood (2025) 146 (Supplement 1): 50.

https://doi.org/10.1182/blood-2025-50

Published: 2025

Journal Articles

DLB class : a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma

Björn Chapuy, Timothy Wood, Chip Stewart, Andrew Dunford, Kirsty Wienand, Sumbul Jawed Khan, Nazli Serin, Meng Wang, Eleonora Calabretta, Joji Shimono, Samantha Van Seters, Sam Wisemann, Saveliy Belkin, David Heimann, Robert Redd, Margaret A. Shipp, Gad Getz

Blood (2025) 145 (18): 2041–2055.

https://doi.org/10.1182/blood.2024025652

Published: 2025

Includes: Supplemental data

Journal Articles

Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Blood (2024) 144 (Supplement 1): 1583.

https://doi.org/10.1182/blood-2024-202943

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 114.

https://doi.org/10.1182/blood-2024-198883

Published: 2024

Journal Articles

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Blood (2024) 144 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2024-211459

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2024-200002

Published: 2024

Journal Articles

MYD88 L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

Elisa Mandato, Qingsheng Yan, Jing Ouyang, Julia Paczkowska, Yan Qin, Yansheng Hao, Kamil Bojarczuk, Julia Hansen, Björn Chapuy, Scott J. Rodig, Sumbul Jawed Khan, Robert A. Redd, Margaret A. Shipp

Blood (2023) 142 (14): 1219–1232.

https://doi.org/10.1182/blood.2023019865

Published: 2023

Includes: Supplemental data

Journal Articles

Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53 -deficient B-cell malignancies

Blood (2022) 139 (25): 3617–3629.

https://doi.org/10.1182/blood.2021014007

Published: 2022

Includes: Supplemental data

Journal Articles

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Blood (2022) 139 (4): 538–553.

https://doi.org/10.1182/blood.2021012081

Published: 2022

Includes: Supplemental data

Journal Articles

A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 712.

https://doi.org/10.1182/blood-2021-146871

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The role of RhoA in diffuse large B-cell lymphoma

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Relapsed diffuse large B-cell lymphoma is shaped by molecular subtypes and genomic alterations

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

DLB class : a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma

Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

MYD88 L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53 -deficient B-cell malignancies

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only